On July 29, Krystal Biotech Inc. rose 6.36% in pre-market trading, trading at $387.38/share, with turnover of $41,300.

On the news front, the company is set to report Q2 earnings on August 3 before market open, with consensus estimates projecting revenue of $122 million (up 32.72% year-over-year), adjusted EPS of $1.69 (up 49.59%), and EBIT growth of 88.66%. The strong outlook follows a significant Q1 beat, where EPS came in at $1.83 versus the FactSet estimate of $1.44, prompting multiple analysts to raise forecasts.

Additionally, Krystal Biotech was recently added to the S&P MidCap 400 index, replacing Taylor Morrison Home, which is being acquired by Berkshire Hathaway. Index inclusion typically drives passive fund inflows. On the fundamental side, the company's core product Vyjuvek secured UK MHRA approval for treating dystrophic epidermolysis bullosa, expanding its international commercial footprint.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)